Drug Profile
Research programme: glucose responsive insulin - Protomer Technologies
Latest Information Update: 16 Jul 2021
Price :
$50
*
At a glance
- Originator Protomer Technologies
- Class
- Mechanism of Action Insulin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 14 Jul 2021 Protomer Technologies has been acquired by Eli Lilly and Company
- 28 Mar 2019 No recent reports of development identified for research development in Type-1 diabetes mellitus in USA
- 25 Feb 2015 JDRF and Sanofi provide up to $4.6 million to Protomer Technologies, Monash University, North Carolina State University and University of Utah to finance development of glucose responsive insulins for Type-1 diabetes mellitus